Delivered contrast volume is the major modifiable risk factor for contrast nephropathy. The AVERT system can divert 31-40% of contrast for peripheral angiography. The upcoming results of the AVERT clinical trial will demonstrate whether the AVERT system reduces contrast nephropathy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ccd.26313 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!